Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharma

Emergent BioSolutions EBS announced today that it has acquired from TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas. Zanolimumab has been evaluated in 130 T-cell lymphoma patients to date. Zanolimumab has received fast track and orphan drug status from the U.S. Food and Drug Administration, and orphan drug status from the European Medicines Agency. Under the terms of the agreement, TenX BioPharma Inc. received a $2.5 million upfront cash payment upon closing. In addition, Emergent will pay TenX BioPharma, Inc. up to $5.5 million if certain development milestones are achieved and royalties on future products sales to third parties. Emergent acquired worldwide rights to all oncology, autoimmune and inflammatory disease indications for zanolimumab and will be responsible for all future costs of developing, manufacturing, and commercializing zanolimumab.